TOMI Environmental Solutions, Inc.
Business
TOMI Environmental Solutions, Inc. is a global provider of bacteria decontamination and infectious disease control solutions that use patented Binary Ionization Technology to generate ionized hydrogen peroxide for indoor air and surface disinfection. Its main products and services include the SteraMist product family (BIT solution, handheld and fogging applicators such as SteraPak, Surface Unit, ENV, NV+, Transport, CES, SIS), consumable solutions, certified decontamination services, IOQ/PQ validation, and the SteraMist Pro Certified program. The company operates across four primary divisions: Life Sciences, Hospital-Healthcare, Food Safety, and Commercial, supported by a TOMI Service Network. TOMI sells domestically and internationally through its internal sales force, exclusive and non‑exclusive representatives, and distributors, maintaining regulatory registrations in the U.S., Canada and numerous other countries.
Summary from filing dated 2025-04-14
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Sales, net | 6 | 8 | 7 | 8 | 8 | |
| Cost of sales | 3 | 4 | 3 | 3 | 3 | |
| Gross profit | 3 | 4 | 4 | 5 | 5 | |
| Professional fees | 742,785 | 597,365 | 575,728 | 536,311 | 538,093 | |
| Depreciation and amortization | 271,329 | 296,536 | 366,677 | 329,164 | 294,665 | |
| Selling expenses | 775,133 | 1 | 1 | 2 | 2 | |
| Research and development | 289,899 | 290,683 | 491,798 | 352,238 | 572,700 | |
| Consulting fees | 317,649 | 225,779 | 282,548 | 215,180 | — | |
| General and administrative | 5 | 5 | 5 | — | — | |
| Total operating expenses | 7 | 8 | 8 | 8 | 10 | |
| Loss from operations | −4 | −4 | −3 | −3 | −5 | |
| Other income (Note 18) | 534,912 | 0 | — | — | — | |
| Interest income | 86,543 | 17,489 | 11,990 | 1,939 | 1,076 | |
| Interest expense | −516,112 | −389,491 | −65,305 | — | — | |
| Total other income (expense) | 105,343 | −372,002 | −53,315 | — | — | |
| Loss before income taxes | −4 | −4 | −3 | −3 | −5 | |
| Provision for income taxes (Note 15) | 0 | 0 | 0 | 0 | −74,086 | |
| Net loss | −4 | −4 | −3 | −3 | −4 | |
| Basic | −0.19 | −0.22 | −0.17 | −0.15 | −0.25 | |
| Diluted | −0.19 | −0.22 | −0.17 | −0.15 | −0.25 | |
| Basic weighted average common shares outstanding | 20 | 20 | 20 | 20 | 18 | |
| Diluted weighted average common shares outstanding | 20 | 20 | 20 | 20 | 18 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 87,775 | 664,879 | 2 | 4 | — | |
| Accounts receivable, net | 689,153 | 2 | 2 | 3 | 2 | |
| Inventories, net (Note 3) | 3 | 4 | 5 | — | — | |
| Vendor deposits (Note 4) | 161,597 | 35,895 | 29,335 | 447,052 | 288,586 | |
| Prepaid expenses | 322,114 | 332,999 | 371,298 | 388,359 | 343,573 | |
| Total current assets | 4 | 6 | 10 | 12 | 13 | |
| Property and equipment, net (Note 5) | 614,311 | 875,449 | 1 | 1 | 1 | |
| Intangible assets, net (Note 6) | 1 | 1 | 1 | — | — | |
| Operating lease - right of use asset (Note 7) | 322,089 | 399,254 | 467,935 | 528,996 | 583,271 | |
| Other assets | 559,671 | 675,348 | 550,677 | 475,103 | 341,006 | |
| Total other assets | 2 | 2 | 2 | 2 | 2 | |
| Total assets | 7 | 10 | 13 | 15 | 16 | |
| Accounts payable | 1 | 2 | 1 | 2 | 1 | |
| Accrued expenses and other current liabilities (Notes 13 and 14) | 860,703 | 455,675 | 675,491 | 728,703 | 664,608 | |
| Deferred revenue | 424,032 | 211,724 | 0 | — | — | |
| Sale of future receipts, net of discount of $113,191 (Note 12) | 254,234 | 0 | — | — | — | |
| Current portion of long-term operating lease (Note 7) | 143,672 | 129,132 | — | — | — | |
| Total current liabilities | 3 | 3 | 2 | 3 | 2 | |
| Long-term operating lease, net of current portion (Note 7) | 370,591 | 513,395 | 642,527 | 761,132 | 861,415 | |
| Convertible notes payable, net of discount of $222,624 and $239,506 at December 31, 2025 and December 31, 2024, respectively (Note 9) | 3 | 2 | 2 | 0 | — | |
| Total long-term liabilities | 3 | 3 | 3 | 761,132 | 861,415 | |
| Total liabilities | 6 | 6 | 5 | 4 | 3 | |
| Commitments and contingencies (Notes 7, 9, 11 and 12) | 0 | 0 | 0 | — | — | |
| Common stock; par value $0.01 per share, 250,000,000 shares authorized; 20,277,205 and 20,015,205 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 202,772 | 200,152 | 199,240 | 197,640 | 196,810 | |
| Additional paid-in capital | 58 | 58 | 58 | 58 | 57 | |
| Accumulated deficit | −58 | −54 | −50 | −46 | −44 | |
| Total shareholders' equity | 588,504 | 4 | 8 | 11 | 14 | |
| Total liabilities and shareholders' equity | 7 | 10 | 13 | 15 | 16 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (Loss) | −4 | −4 | −3 | −3 | — | |
| Amortization of right of use asset | 157,315 | 157,315 | 157,315 | 157,315 | 157,315 | |
| Amortization of deferred financing costs | 70,939 | 62,480 | 10,413 | 0 | — | |
| Origination fees | 15,000 | 0 | — | — | — | |
| Equity compensation expense | 147,000 | 144,307 | 163,286 | — | — | |
| Shares issued to directors | 51,000 | 45,000 | — | — | — | |
| Credit loss expense | 267,309 | 1 | 272,517 | — | — | |
| Inventory reserve | 0 | 1 | — | — | — | |
| Sales returns allowance | 104,781 | 227,000 | 128,390 | — | — | |
| Accounts receivable | 819,895 | −470,512 | — | — | — | |
| Inventory | 637,376 | 60,363 | — | — | — | |
| Prepaid expenses | 70,554 | 38,299 | — | — | — | |
| Vendor deposits | −125,702 | −6,560 | — | — | — | |
| Other assets | 115,677 | −5,321 | — | — | — | |
| Accounts payable | −271,476 | 657,349 | −494,721 | 707,711 | −447,429 | |
| Accrued expenses | 178,258 | −219,816 | — | — | — | |
| Deferred revenue | 212,308 | 159,724 | −699,732 | — | — | |
| Lease liability | −169,220 | −165,098 | −160,291 | −155,622 | — | |
| Net Cash (Used) in Operating Activities | −1 | −1 | −4 | −1 | −4 | |
| Capitalized patent and trademark costs | −130,412 | −153,636 | −118,630 | −40,570 | — | |
| Purchase of property and equipment | −5,165 | −107,891 | −98,060 | −200,876 | — | |
| Net Cash (Used) in Investing Activities | −135,577 | −261,527 | −216,690 | −241,446 | −639,366 | |
| Proceeds from issuance of convertible notes | 535,000 | 0 | 2 | — | — | |
| Proceeds from sale of future receipts, net of origination fees | 300,000 | 0 | — | — | — | |
| Repayments of sale of future receipts | −79,875 | 0 | — | — | — | |
| Proceeds from exercise of options | 0 | 27,500 | 0 | 25,000 | 0 | |
| Net Cash Provided by Financing Activities | 755,125 | 27,500 | 2 | 25,000 | 5 | |
| (Decrease) in Cash and Cash Equivalents | −577,104 | −2 | −2 | −1 | 118,602 | |
| Cash paid for interest | 437,474 | 312,000 | 0 | 28,892 | 0 | |
| Cash paid (refunded) for income taxes | 0 | 0 | 0 | −72,086 | 75,000 | |
| Service equipment reclassified from inventory to fixed assets | 14,397 | 0 | — | — | — |